Plant Name: Solanum aculeatissimum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| CTDSP1; RECQL; TDP1; PKM; GLO1; ALOX12; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; NOX4; USP2; TNKS; PARP1; TNKS2; CD38; POLB; | |
| ACHE; | |
| CFTR; | |
| GSK3B; DAPK1; SYK; FLT3; EGFR; CDK6; CSNK2A1; | |
| CA2; CA12; CA9; CA7; CA4; | |
| AR; | |
| ESR2; ESR1; | |
| THRB; | |
| ESRRA; | |
| ALOX5; TYR; MAOA; PTGS2; XDH; | |
| KDM4E; | |
| MMP9; MMP12; MMP2; | |
| AHR; HIF1A; TP53; | |
| ABCG2; ABCC1; | |
| NPC1; LMNA; TTR; MAPT; THPO; APP; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.356E-13 | 3.846E-10 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.785E-12 | 2.637E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.402E-11 | 1.803E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NOX4, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.157E-10 | 6.145E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.463E-10 | 7.065E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.360E-09 | 4.777E-07 | CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.068E-09 | 7.035E-07 | AR, CA12, CA2, CA4, CA7, CA9, ESR1, ESR2, ESRRA, GLO1, MMP12, MMP2, MMP9, PARP1, THRB, TNKS, TP53 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 6.332E-09 | 1.920E-06 | CA2, CA7, CFTR, EGFR, HIF1A, NPC1, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 9.068E-09 | 2.564E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 9.346E-09 | 2.609E-06 | CA2, CA7, CD38, CDK6, CFTR, EGFR, HIF1A, NPC1, PARP1, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.653E-09 | 2.661E-06 | CA12, CA2, CA4, CA7, CA9, CFTR |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.862E-08 | 4.667E-06 | ABCG2, ACHE, APP, CD38, CSNK2A1, DAPK1, EGFR, ESR1, ESR2, FLT3, MAPT, MMP9, PARP1, PKM, PTGS2, SMN1, SMN2, TP53, TTR, TYR, USP2, XDH |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 2.105E-08 | 5.037E-06 | AR, CYP3A4, ESR1, ESR2, ESRRA, HSD17B1, NPC1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.806E-08 | 1.385E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.806E-08 | 1.385E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 7.368E-08 | 1.472E-05 | ABCC1, ALOX12, ALOX15, ALOX5, SYK |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.613E-07 | 3.080E-05 | CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.665E-07 | 3.125E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.476E-07 | 4.419E-05 | ALOX12, ALOX15, ALOX5, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 6.528E-07 | 1.061E-04 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| MF | GO:0005488; binding | GO:0070324; thyroid hormone binding | 1.446E-06 | 2.044E-04 | PKM, THRB, TTR |
| BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 1.704E-06 | 2.348E-04 | AHR, APP, AR, CD38, CSNK2A1, CTDSP1, CYP2D6, DAPK1, ESR1, ESR2, ESRRA, GSK3B, HIF1A, MAPT, MMP12, MMP9, NPC1, PARP1, PTGS2, THRB, TNKS, TNKS2, TP53, USP2, XDH |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 3.453E-06 | 4.371E-04 | APP, EGFR, MAPT |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 4.689E-06 | 5.868E-04 | AHR, CSNK2A1, HIF1A, MAPT |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 4.899E-06 | 6.087E-04 | CD38, CYP1A2, EGFR, ESR1, ESRRA, PTGS2 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 4.920E-06 | 6.087E-04 | CA2, CA7, CFTR |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 6.748E-06 | 8.029E-04 | AR, CYP19A1, ESR1 |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 7.089E-06 | 8.390E-04 | AKR1B1, EGFR, MMP2, MMP9, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 1.030E-05 | 1.144E-03 | CYP1A1, EGFR, PTGS2, TP53, TYR |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.164E-05 | 1.267E-03 | CYP19A1, HSD17B1, HSD17B2 |
| MF | GO:0005488; binding | GO:0019899; enzyme binding | 1.172E-05 | 1.270E-03 | APP, AR, CFTR, CYP1A1, CYP1A2, CYP2C19, CYP3A4, EGFR, ESR1, ESR2, GSK3B, HIF1A, MAPT, PARP1, POLB, PTGS2, SYK, THRB, TNKS2, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.221E-05 | 1.291E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.221E-05 | 1.291E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.221E-05 | 1.291E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 1.542E-05 | 1.577E-03 | APP, CDK6, EGFR, GSK3B, HIF1A, MAPT, PARP1, PTGS2, SYK, TP53, XDH |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.656E-05 | 1.662E-03 | CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, EGFR, HSD17B2, NOX4, PTGS2 |
| BP | GO:0032501; multicellular organismal process | GO:0045780; positive regulation of bone resorption | 1.842E-05 | 1.823E-03 | CA2, EGFR, SYK |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.861E-05 | 1.834E-03 | ACHE, CD38, CFTR, EGFR, HIF1A, MMP12, SYK |
| BP | GO:0065007; biological regulation | GO:0044093; positive regulation of molecular function | 2.369E-05 | 2.293E-03 | APP, AR, CFTR, DAPK1, EGFR, ESR1, ESR2, FLT3, GSK3B, HIF1A, MAPT, MMP9, NOX4, PARP1, SYK, TNKS, TSHR, XDH |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 3.489E-05 | 3.219E-03 | AHR, AR, ESR1, ESR2, ESRRA, THRB |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 3.655E-05 | 3.289E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.655E-05 | 3.289E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 3.655E-05 | 3.289E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.655E-05 | 3.289E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 3.655E-05 | 3.289E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 3.655E-05 | 3.289E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 3.890E-05 | 3.471E-03 | NOX4, PARP1, POLB, TP53 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 3.922E-05 | 3.471E-03 | AKR1B1, CYP1B1, EGFR, MMP9, TP53 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 3.922E-05 | 3.471E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 4.905E-05 | 4.176E-03 | ABCC1, CA2, CA4, CA9, EGFR, TSHR |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 5.303E-05 | 4.459E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 5.945E-05 | 4.887E-03 | AKR1B1, CDK6, CFTR, CYP1B1, EGFR, PTGS2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0009416; response to light stimulus | 6.354E-05 | 5.087E-03 | APP, EGFR, HIF1A, PTGS2, TP53, TYR, USP2 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 6.561E-05 | 5.214E-03 | CSNK2A1, DAPK1, EGFR, FLT3, GSK3B, SYK |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 7.026E-05 | 5.504E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 7.294E-05 | 5.612E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 7.294E-05 | 5.612E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 7.294E-05 | 5.612E-03 | ESR1, ESR2 |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 8.358E-05 | 6.276E-03 | ACHE, AKR1B1, APP, CA4, EGFR, NOX4, NPC1, TNKS2, TYR, USP2 |
| BP | GO:0065007; biological regulation | GO:0043281; regulation of cysteine-type endopeptidase activity involved in apoptotic process | 8.637E-05 | 6.463E-03 | CSNK2A1, DAPK1, MAPT, MMP9, PTGS2, XDH |
| BP | GO:0008152; metabolic process | GO:0051172; negative regulation of nitrogen compound metabolic process | 8.669E-05 | 6.465E-03 | AHR, APP, AR, CD38, CSNK2A1, CTDSP1, DAPK1, EGFR, ESR1, ESR2, ESRRA, MMP12, MMP9, PARP1, PTGS2, THRB, TNKS, TNKS2, TP53, USP2, XDH |
| BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 8.816E-05 | 6.552E-03 | APP, CFTR, CYP19A1, CYP1B1, NPC1 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 9.487E-05 | 6.863E-03 | AR, ESR1, ESR2, ESRRA, THRB |
| BP | GO:0009987; cellular process | GO:2001234; negative regulation of apoptotic signaling pathway | 9.854E-05 | 7.082E-03 | AR, DAPK1, HIF1A, LMNA, MMP9, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.024E-04 | 7.262E-03 | CYP19A1, CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 1.024E-04 | 7.262E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0007610; behavior | GO:0007610; behavior | 1.109E-04 | 7.787E-03 | APP, EGFR, HIF1A, MAPT, NPC1, PTGS2, THRB, TP53, USP2 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 1.149E-04 | 7.967E-03 | CYP1B1, HIF1A, PTGS2 |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 1.149E-04 | 7.967E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 1.149E-04 | 7.967E-03 | APP, GSK3B, PARP1 |
| BP | GO:0048511; rhythmic process | GO:0007623; circadian rhythm | 1.174E-04 | 8.088E-03 | AHR, EGFR, GSK3B, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.213E-04 | 8.253E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.213E-04 | 8.253E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 1.283E-04 | 8.653E-03 | CYP19A1, CYP3A4, ESR1 |
| BP | GO:0008152; metabolic process | GO:0034641; cellular nitrogen compound metabolic process | 1.316E-04 | 8.788E-03 | ABCG2, ACHE, AHR, APP, AR, CD38, CSNK2A1, CYP1B1, CYP2C9, CYP2D6, CYP3A4, EGFR, ESR1, ESR2, ESRRA, GLO1, HIF1A, HSD17B10, KDM4E, MAOA, PARP1, PKM, POLB, PTGS2, RECQL, SMN1, SMN2, TDP1, THRB, TP53, TTR, XDH |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 1.360E-04 | 8.999E-03 | AKR1B1, CD38, EGFR, HSD17B2, MMP2, PTGS2, TP53 |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 1.401E-04 | 9.241E-03 | ALOX15, ESR1, GSK3B, MAPT, PARP1, TP53 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.489E-04 | 9.650E-03 | CSNK2A1, EGFR, FLT3, PKM |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.841E-14 | 6.433E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NOX4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.402E-10 | 2.603E-08 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.461E-10 | 2.236E-08 | CYP2C9; APP; CYP2D6; MAOA; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.002E-09 | 5.113E-08 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.777E-08 | 4.532E-07 | MAOA; ALOX15; AKR1B1; ALOX12; PTGS2; CYP2C19; CYP3A4; TYR; CYP19A1; HSD17B10; CYP2C9; PKM; HSD17B1; ALOX5; HSD17B2; CYP1A2; CYP1A1; CD38; XDH |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 9.128E-08 | 1.552E-06 | AR; GSK3B; CDK6; FLT3; DAPK1; MMP2; PTGS2; HIF1A; TP53; MMP9; EGFR |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.189E-08 | 3.638E-07 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.527E-08 | 1.248E-06 | CYP2C9; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.249E-07 | 1.911E-06 | CYP2C9; MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.345E-09 | 8.970E-08 | CA12; CA2; CA4; CA7; CA9 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.755E-07 | 2.441E-06 | CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.361E-08 | 9.531E-07 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.666E-07 | 3.400E-06 | DAPK1; MMP2; MMP9; TP53; EGFR |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.210E-06 | 3.777E-05 | PKM; FLT3; TP53; HIF1A; EGFR |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.186E-05 | 2.229E-04 | MMP2; ESR1; MMP9; EGFR; ESR2 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 6.585E-05 | 5.635E-04 | MMP2; TP53; HIF1A; ESR1; MMP9; EGFR |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.018E-05 | 1.113E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 5.087E-05 | 4.864E-04 | GSK3B; THRB; TP53; ESR1; HIF1A |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 6.629E-05 | 5.635E-04 | ABCC1; CDK6; CYP1B1; PTGS2; TP53; MMP9; EGFR |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 7.078E-05 | 5.699E-04 | CYP2C9; CYP1A2; CYP1A1; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.401E-04 | 1.670E-03 | GSK3B; AR; TP53; EGFR |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.000E-04 | 7.652E-04 | CA2; CYP3A4; CFTR; ABCG2 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 6.224E-04 | 3.809E-03 | GSK3B; SYK; CSNK2A1; CD38; TP53 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 6.653E-04 | 3.915E-03 | POLB; CDK6; PKM; SYK; TP53 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.842E-04 | 1.890E-03 | SYK; CSNK2A1; PARP1; PTGS2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.189E-03 | 6.276E-03 | GSK3B; CDK6; CSNK2A1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 9.160E-04 | 5.005E-03 | CDK6; TP53; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.412E-03 | 7.203E-03 | CDK6; TP53; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 7.374E-04 | 4.179E-03 | GSK3B; TP53; EGFR |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.576E-03 | 1.159E-02 | APP; GSK3B; MAPT; HSD17B10 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.476E-03 | 7.284E-03 | CDK6; TP53; EGFR |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.821E-03 | 8.708E-03 | CDK6; TP53; EGFR |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.896E-03 | 8.790E-03 | GSK3B; ESR1; ESR2 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 6.066E-03 | 2.320E-02 | GSK3B; CDK6; SYK; TP53; EGFR |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 4.506E-04 | 2.872E-03 | ABCC1; CFTR; ABCG2 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.145E-03 | 1.337E-02 | CDK6; PTGS2; TP53 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 3.356E-03 | 1.388E-02 | THPO; FLT3; CD38 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 4.286E-03 | 1.726E-02 | CA2; CD38; CFTR |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.208E-02 | 4.017E-02 | PARP1; LMNA; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.052E-02 | 3.640E-02 | GSK3B; TP53; EGFR |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 8.697E-03 | 3.094E-02 | GSK3B; CDK6; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.352E-02 | 4.308E-02 | CDK6; TP53; MMP9 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.255E-02 | 4.085E-02 | GSK3B; CSNK2A1; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.559E-02 | 4.769E-02 | PTGS2; TSHR |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.506E-02 | 4.703E-02 | GSK3B; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.071E-02 | 3.640E-02 | CYP3A4; XDH |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 8.174E-03 | 2.978E-02 | PKM; GLO1 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 6.304E-03 | 2.352E-02 | MAOA; TYR |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 5.619E-03 | 2.204E-02 | POLB; PARP1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.752E-03 | 1.203E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.132E-04 | 8.244E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR; AKR1B1 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | SYK; HIF1A; TP53; FLT3; CA9; MMP9; EGFR; MMP2; PKM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| NA: NA | HIV infections | NA | AHR |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; EGFR; PARP1 |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PTGS2; PTGS2; ABCC1; ESRRA |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; THRB |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; CD38 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53; CD38 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9; EGFR; EGFR |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; SYK; SYK; MMP12; PTGS2; ESRRA |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; ESR1; PTGS2; PTGS2; PTGS2; PTGS2; PKM |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1; MMP2; ESRRA |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; EGFR; MMP2; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; MMP12; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; EGFR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; MAOA |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR; PARP1; MMP2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; EGFR; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; ACHE; ACHE; ACHE; MAOA; PTGS2; MAPT; APP |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; SYK; HIF1A; TP53; FLT3; FLT3; CA9; MMP9; ACHE; EGFR; ESR1; ESR1; PARP1; MMP2; PTGS2; CD38; APP; CSNK2A1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; PARP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; SYK; AKR1B1; PTGS2; PTGS2; PTGS2; PTGS2; ESRRA |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; EGFR; EGFR; EGFR; ESR1; ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR; PTGS2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; EGFR |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; PTGS2; ABCC1; ABCC1 |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR; APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |